Novo Nordisk stock fell Monday after it said its next-generation weight loss drug didn’t meet its key goal of showing that it wasn’t inferior to Eli Lilly’s rival drug, in the latest blow to the Danish drugmaker, whose stock is trading at a multi-year low after a series of disappointing announcements.
